{"id":38276,"date":"2025-07-31T12:27:50","date_gmt":"2025-07-31T04:27:50","guid":{"rendered":"https:\/\/flcube.com\/?p=38276"},"modified":"2025-07-31T12:27:51","modified_gmt":"2025-07-31T04:27:51","slug":"sanofis-sar446523-gains-fda-orphan-drug-status-for-relapsed-or-refractory-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=38276","title":{"rendered":"Sanofi’s SAR446523 Gains FDA Orphan Drug Status for Relapsed or Refractory Multiple Myeloma"},"content":{"rendered":"\n

French pharmaceutical major Sanofi (NASDAQ: SNY<\/a>)\u00a0 reported that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its investigational GPRC5D-targeting antibody, SAR446523, for the treatment of relapsed or refractory multiple myeloma (R\/R MM). The monoclonal antibody is designed to enhance antibody-dependent cellular cytotoxicity (ADCC) activity and is currently under evaluation in a first-in-human Phase I trial.<\/p>\n\n\n\n

Mechanism and Target of SAR446523<\/strong>
SAR446523 represents an IgG1 monoclonal antibody characterized by its enhanced ADCC activity. It specifically targets the GPRC5D receptor, which is abundantly expressed on malignant plasma cells in myeloma patients but present at minimal levels in healthy tissues. This selective targeting may offer a more precise treatment approach for patients with R\/R MM.<\/p>\n\n\n\n

Unmet Medical Need and Therapeutic Potential<\/strong>
Sanofi acknowledged that despite the existence of several treatment options, multiple myeloma remains an incurable disease, with most patients experiencing relapse and developing resistance to current therapies. The high attrition rate in later lines of treatment underscores the critical need for more effective front-line therapies. The development of SAR446523 aims to address this gap by providing a novel targeted option for patients who no longer respond to existing treatments.<\/p>\n\n\n\n

Current Development Status<\/strong>
The safety and efficacy of SAR446523 are still under investigation through a Phase I trial assessing its subcutaneous administration. Regulatory authorities have not yet evaluated the drug, and Sanofi continues to advance its clinical development program with the goal of potentially improving outcomes for patients with multiple myeloma.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

French pharmaceutical major Sanofi (NASDAQ: SNY)\u00a0 reported that the U.S. Food and Drug Administration (FDA)…<\/p>\n","protected":false},"author":1,"featured_media":38277,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,867,15,24,147],"class_list":["post-38276","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-nasdaq-sny","tag-product-approvals","tag-rare-orphan-disease-drugs","tag-sanofi"],"yoast_head":"\nSanofi's SAR446523 Gains FDA Orphan Drug Status for Relapsed or Refractory Multiple Myeloma - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"French pharmaceutical major Sanofi (NASDAQ: SNY)\u00a0 reported that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its investigational GPRC5D-targeting antibody, SAR446523, for the treatment of relapsed or refractory multiple myeloma (R\/R MM). The monoclonal antibody is designed to enhance antibody-dependent cellular cytotoxicity (ADCC) activity and is currently under evaluation in a first-in-human Phase I trial.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=38276\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi's SAR446523 Gains FDA Orphan Drug Status for Relapsed or Refractory Multiple Myeloma\" \/>\n<meta property=\"og:description\" content=\"French pharmaceutical major Sanofi (NASDAQ: SNY)\u00a0 reported that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its investigational GPRC5D-targeting antibody, SAR446523, for the treatment of relapsed or refractory multiple myeloma (R\/R MM). The monoclonal antibody is designed to enhance antibody-dependent cellular cytotoxicity (ADCC) activity and is currently under evaluation in a first-in-human Phase I trial.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=38276\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-31T04:27:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-31T04:27:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3108.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38276#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38276\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi’s SAR446523 Gains FDA Orphan Drug Status for Relapsed or Refractory Multiple Myeloma\",\"datePublished\":\"2025-07-31T04:27:50+00:00\",\"dateModified\":\"2025-07-31T04:27:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38276\"},\"wordCount\":266,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38276#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/3108.webp\",\"keywords\":[\"Cancer\",\"NASDAQ: SNY\",\"Product approvals\",\"Rare \\\/ orphan disease drugs\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38276#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38276\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=38276\",\"name\":\"Sanofi's SAR446523 Gains FDA Orphan Drug Status for Relapsed or Refractory Multiple Myeloma - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38276#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38276#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/3108.webp\",\"datePublished\":\"2025-07-31T04:27:50+00:00\",\"dateModified\":\"2025-07-31T04:27:51+00:00\",\"description\":\"French pharmaceutical major Sanofi (NASDAQ: SNY)\u00a0 reported that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its investigational GPRC5D-targeting antibody, SAR446523, for the treatment of relapsed or refractory multiple myeloma (R\\\/R MM). The monoclonal antibody is designed to enhance antibody-dependent cellular cytotoxicity (ADCC) activity and is currently under evaluation in a first-in-human Phase I trial.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38276#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38276\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38276#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/3108.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/3108.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sanofi's SAR446523 Gains FDA Orphan Drug Status for Relapsed or Refractory Multiple Myeloma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38276#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi’s SAR446523 Gains FDA Orphan Drug Status for Relapsed or Refractory Multiple Myeloma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi's SAR446523 Gains FDA Orphan Drug Status for Relapsed or Refractory Multiple Myeloma - Insight, China's Pharmaceutical Industry","description":"French pharmaceutical major Sanofi (NASDAQ: SNY)\u00a0 reported that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its investigational GPRC5D-targeting antibody, SAR446523, for the treatment of relapsed or refractory multiple myeloma (R\/R MM). The monoclonal antibody is designed to enhance antibody-dependent cellular cytotoxicity (ADCC) activity and is currently under evaluation in a first-in-human Phase I trial.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=38276","og_locale":"en_US","og_type":"article","og_title":"Sanofi's SAR446523 Gains FDA Orphan Drug Status for Relapsed or Refractory Multiple Myeloma","og_description":"French pharmaceutical major Sanofi (NASDAQ: SNY)\u00a0 reported that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its investigational GPRC5D-targeting antibody, SAR446523, for the treatment of relapsed or refractory multiple myeloma (R\/R MM). The monoclonal antibody is designed to enhance antibody-dependent cellular cytotoxicity (ADCC) activity and is currently under evaluation in a first-in-human Phase I trial.","og_url":"https:\/\/flcube.com\/?p=38276","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-31T04:27:50+00:00","article_modified_time":"2025-07-31T04:27:51+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3108.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=38276#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=38276"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi’s SAR446523 Gains FDA Orphan Drug Status for Relapsed or Refractory Multiple Myeloma","datePublished":"2025-07-31T04:27:50+00:00","dateModified":"2025-07-31T04:27:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=38276"},"wordCount":266,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=38276#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3108.webp","keywords":["Cancer","NASDAQ: SNY","Product approvals","Rare \/ orphan disease drugs","Sanofi"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=38276#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=38276","url":"https:\/\/flcube.com\/?p=38276","name":"Sanofi's SAR446523 Gains FDA Orphan Drug Status for Relapsed or Refractory Multiple Myeloma - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=38276#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=38276#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3108.webp","datePublished":"2025-07-31T04:27:50+00:00","dateModified":"2025-07-31T04:27:51+00:00","description":"French pharmaceutical major Sanofi (NASDAQ: SNY)\u00a0 reported that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its investigational GPRC5D-targeting antibody, SAR446523, for the treatment of relapsed or refractory multiple myeloma (R\/R MM). The monoclonal antibody is designed to enhance antibody-dependent cellular cytotoxicity (ADCC) activity and is currently under evaluation in a first-in-human Phase I trial.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=38276#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=38276"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=38276#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3108.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3108.webp","width":1080,"height":608,"caption":"Sanofi's SAR446523 Gains FDA Orphan Drug Status for Relapsed or Refractory Multiple Myeloma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=38276#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi’s SAR446523 Gains FDA Orphan Drug Status for Relapsed or Refractory Multiple Myeloma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3108.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38276","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38276"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38276\/revisions"}],"predecessor-version":[{"id":38278,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38276\/revisions\/38278"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/38277"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38276"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38276"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38276"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}